This activity expired on April 4, 2025; credit is no longer available.

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Media: Enduring Material
Activity Release Date: April 5, 2024
Activity Expiration Date: April 4, 2025
Time to Complete Activity: 45 minutes

Activity Description

Enhance your expertise in developing modern sequential treatment with BTK inhibitor (BTKi) options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)! This educational activity, led by a CLL care expert, delves into the critical distinctions between covalent and non-covalent BTK inhibitors, explores strategic approaches to prognostic factor testing to inform treatment selection and planning, and provides guidance on the safe sequential use of BTKi in patients progressing on treatment. Throughout, question-based assessments will offer you a customized learning experience designed to build skills for the effective management of patients with R/R CLL.

This program is also part of a larger curriculum developed in collaboration with CLL Society. For more information about useful point-of-care tools and educational resources that can be shared with your patients and used to encourage collaborative care, please view other components of this series: PeerView.com/HGE. Collected CLL Society resources can be found here: PeerView.com/onDemand/programs/150209250-2/downloads/PVI_practiceaids_HGE.pdf.

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology physician specialists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
• Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
• Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
• Employ team-based approaches to address practical aspects of CLL management when using BTKi, including coordinating care, formulary planning, educating patients, dosing, and managing treatment-related AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-046-H01-P
Type of Activity: Knowledge

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/4/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 4, 2025; credit is no longer available.

From Resistance to Resilience in R/R CLL: Sequencing Strategies for Achieving Effective Continuous Care

Media: Enduring Material
Activity Release Date: April 5, 2024
Activity Expiration Date: April 4, 2025
Time to Complete Activity: 45 minutes

Activity Description

Enhance your expertise in developing modern sequential treatment with BTK inhibitor (BTKi) options for relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)! This educational activity, led by a CLL care expert, delves into the critical distinctions between covalent and non-covalent BTK inhibitors, explores strategic approaches to prognostic factor testing to inform treatment selection and planning, and provides guidance on the safe sequential use of BTKi in patients progressing on treatment. Throughout, question-based assessments will offer you a customized learning experience designed to build skills for the effective management of patients with R/R CLL.

This program is also part of a larger curriculum developed in collaboration with CLL Society. For more information about useful point-of-care tools and educational resources that can be shared with your patients and used to encourage collaborative care, please view other components of this series: PeerView.com/HGE. Collected CLL Society resources can be found here: PeerView.com/onDemand/programs/150209250-2/downloads/PVI_practiceaids_HGE.pdf.

Target Audience

This activity has been designed to meet the educational needs of hematology-oncology physician specialists, NPs, PAs, nurses, pharmacists, and other care team professionals involved in the management of patients with R/R CLL.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Summarize the mechanistic, selectivity, and safety differences among covalent and non-covalent BTKi, including off-target effects, therapeutic intolerance, and mechanisms of BTK resistance
• Implement best practices for capturing relevant prognostic factors, disease progression, and therapeutic intolerance to guide treatment planning with BTKi in R/R CLL
• Formulate effective sequential treatment plans with BTKi strategies in CLL based on current evidence, prognostic information, and other patient- and disease-specific factors
• Employ team-based approaches to address practical aspects of CLL management when using BTKi, including coordinating care, formulary planning, educating patients, dosing, and managing treatment-related AEs

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Meghan C. Thompson, MD
Assistant Attending L1, Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, New York

Meghan C. Thompson, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Lilly/Loxo Oncology, Inc.; and Pharmacyclics LLC/Janssen Pharmaceuticals, Inc.
Grant/Research Support from AbbVie; AstraZeneca; BeiGene, Inc.; Genentech, Inc.; Genmab; and Nurix Therapeutics. Research funding goes to institution.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and CLL Society. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Lilly.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.75 contact hour(s) and 0.75 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.75 contact hours (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number: JA4008289-9999-24-046-H01-P
Type of Activity: Knowledge

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 4/4/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 21, 2025; credit is no longer available.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

• Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
• Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
• Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 21, 2025; credit is no longer available.

Accelerating Remission in Multiple Myeloma: Updates on CAR-T, BCMA Antibodies, and Achieving Deep Responses & Enduring Efficacy

Activity Description and Educational Objectives

Are you prepared to learn about BCMA strategies that will help you accelerate the achievement of deep and durable remissions in multiple myeloma (MM)? New evidence is pointing to the use of chimeric antigen receptor T-cell (CAR-T) constructs for MM in earlier lines of therapy, which will have implications for sequencing with other BCMA options. At the same time, “off-the-shelf” BCMA antibodies are transforming treatment choices in pretreated disease, offering clinicians another tool to achieve deep remissions. This activity features expert exchanges based around real-world patient cases that illustrate the central role of BCMA bispecifics and CAR-T therapy throughout the MM therapeutic journey. Each case conversation is linked to a short overview of the evidence supporting the experts’ treatment choices. Don’t miss this opportunity to “accelerate remission” and learn how to apply new science on BCMA platforms!

Upon completion of this activity, participants should be better able to:

• Cite the safety and efficacy evidence supporting the use of established and emerging anti-BCMA platforms, including CAR-T and off-the-shelf antibody options, across several lines of therapy in MM
• Integrate evidence-informed anti-BCMA platforms into customized sequential treatment plans for MM, including in early relapse and more heavily pretreated disease
• Develop protocols to address practical aspects of anti-BCMA therapy, including planning for referral to specialized care, using appropriate bridging regimens, considering off-the-shelf antibody therapy, and understanding dosing and AE management

Target Audience

This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, transplant and cellular therapy physician and nurse specialists, and other clinicians involved in the management of multiple myeloma.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no prerequisites and there is no fee to participate in this activity or to receive CME/NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: March 22, 2024 - March 21, 2025
Time to Complete: 60 minutes

Faculty and Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Co-Chair & Moderator
Krina Patel, MD, MSc
Associate Professor, Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Krina Patel, MD, MSc, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie; AstraZeneca; Bristol Myers Squibb; Celgene Corporation; Curio Bioscience; Janssen Pharmaceuticals, Inc.; Karyopharm; Legend Biotech; Merck & Co., Inc.; Oncopeptides; Pfizer; and Precision BioSciences, Inc.
Grant/Research Support from AbbVie; Allogene Therapeutics, Inc.; Arcellx; Bristol Myers Squibb; Celgene Corporation; Cellectis; Janssen Pharmaceuticals, Inc.; Nektar Therapeutic; Poseida Therapeutics; Precision BioSciences, Inc.; and Takeda Pharmaceuticals U.S.A., Inc.

Co-Chair & Presenter
Hans Lee, MD
Associate Professor, Department of Lymphoma/Myeloma
Director, Multiple Myeloma Clinical Research
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Hans Lee, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Allogene Therapeutics; Bristol Myers Squibb; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Pfizer; Regeneron Pharmaceuticals, Inc.; Sanofi; and Takeda Pharmaceutical Company Limited.
Grant/Research Support from Amgen; Bristol Myers Squibb; GlaxoSmithKline; Janssen Pharmaceuticals, Inc.; Regeneron Pharmaceuticals, Inc.; and Takeda Pharmaceutical Company Limited.

Medical Director
Carmine DeLuca
PVI, PeerView Institute for Medical Education

Carmine DeLuca has no financial interests/relationships or affiliations in relation to this activity.

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

Accreditation, Credit, and Support

The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

This activity was developed in collaboration with our educational partner, PVI, PeerView Institute for Medical Education.

Physicians

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Support

This activity is supported through independent medical educational grants from Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Regeneron Pharmaceuticals, Inc.

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

About This CME/NCPD Activity

PVI, PeerView Institute for Medical Education, and The Medical College of Wisconsin are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and The Medical College of Wisconsin.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 17, 2025; credit is no longer available.

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.

Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
• Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
• Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on April 17, 2025; credit is no longer available.

Redefining Endometrial and Ovarian Carcinoma Care: Maximizing the Clinical Potential of Immunotherapy, ADCs, PARP Inhibitors, and Other Emerging Treatment Strategies

Media: Enduring Material

Activity Release Date: March 18, 2024

Activity Expiration Date: April 17, 2025

Time to Complete Activity: 75 minutes

Activity Description

Which treatment advances are charting new standards of care for patients with endometrial or ovarian cancer? Use of immunotherapy-based approaches, ADCs, PARP inhibitors, and other innovative strategies have brought new hope for better outcomes in these gynecologic cancers, with many approvals and other strategies in late-stage development in a variety of settings.

Join PeerView, the National Ovarian Cancer Coalition, and the Foundation for Women’s Cancers for a new expert-led video designed to bring learners the latest evidence on approved and emerging treatment strategies and practical guidance on incorporating effective treatments, including via clinical trial enrollment, into patient care. Learn where approved and emerging treatments fit into therapeutic algorithms for ovarian and endometrial cancer, how companion diagnostics guide individualized treatment selection, and best practices for collaborative, team-based management of treatment-related adverse events. Participate now and help redefine optimal care for your patients.

Target Audience

This activity has been designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; obstetrician-gynecologists; advanced practice clinicians; nurses; and other healthcare professionals involved in the care of patients with endometrial or ovarian cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Review the rationale and efficacy and safety evidence for immunotherapy regimens, antibody-drug conjugates, PARP inhibitors, and other innovative approaches for patients with endometrial or ovarian cancer
• Develop individualized therapeutic plans, including via clinical trial enrollment, utilizing the latest biomarker data and guideline-recommended treatment algorithms for eligible patients with endometrial or ovarian cancer
• Implement collaborative, team-based strategies to mitigate and manage treatment-related AEs for patients with endometrial or ovarian cancer receiving modern therapeutic approaches, including use of immunotherapy, antibody-drug conjugates, and PARP inhibitors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Kathleen N. Moore, MD, MS

Deputy Director

Associate Director, Clinical Research

Virginia Kerley Cade Chair in Developmental Therapeutics

Co-Director, Cancer Therapeutics Program

Stephenson Cancer Center at the University of Oklahoma HSC

Oklahoma City, Oklahoma

Kathleen N. Moore, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Alkermes; Aravive; AstraZeneca; Blueprint Medicines Corporation; Caris Life Sciences; Clovis Oncology; Eisai Inc.; Elevar Therapeutics; Genentech, Inc./F. Hoffmann-La Roche Ltd; GlaxoSmithKline/Tesaro, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; InxMed; Lilly; Merck & Co., Inc.; Mersana Therapeutics; Myriad Genetics, Inc.; Novartis Pharmaceuticals Corporation; Onconova Therapeutics; OncXerna Therapeutics, Inc.; Tarveda Therapeutics; The GOG Foundation Inc; VBL Therapeutics; and Verastem, Inc.

Grant/Research Support from GlaxoSmithKline/Tesaro, Inc.; Lilly; Merck & Co., Inc.; PTC Therapeutics; and Verastem, Inc.

Faculty/Planner

Floor J. Backes, MD

Professor

Fellowship Director

Director of Clinical Research

Division of Gynecologic Oncology

Department of Obstetrics and Gynecology

The Ohio State University College of Medicine

The James Cancer Hospital and Solove Research Institute

Columbus, Ohio

Floor J. Backes, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; BioNTech SE.; Clovis Oncology; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Myriad Genetics, Inc.

Grant/Research Support from AstraZeneca; Clovis Oncology; Eisai Inc.; GlaxoSmithKline; ImmunoGen, Inc.; Merck & Co., Inc.; Natera, Inc.

Speaker for The GOG Foundation Inc.

Faculty/Planner

Bhavana Pothuri, MD, MS

Professor, Departments of Ob/Gyn and Medicine, NYU Grossman School of Medicine

Medical Director, Clinical Trials Office (CTO), Laura and Isaac Perlmutter Cancer Center

Director, Gynecologic Oncology Clinical Trials

New York, New York

Director, Diversity and Health Equity for Clinical Trials, GOG Foundation

Associate Clinical Trials Advisor, Ovarian and Endometrial Cancer, GOG Partners

Bhavana Pothuri, MD, MS, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Celsion Corporation/Immune Pharmaceuticals Inc.; I-MAB Biopharma Co., Ltd; InxMed; Merck & Co., Inc.; Mersana Therapeutics; Nuvation Bio, Inc.; Onconova Therapeutics; Sutro Biopharma, Inc.; Tesaro, Inc./GlaxoSmithKline; The GOG Foundation Inc; and Toray Group.

Grant/Research Support from Acrivon Therapeutics; Agenus Inc.; AstraZeneca; Celgene Corporation; Celsion Corporation/Immune Pharmaceuticals Inc.; Clovis Oncology; Eisai Co., Ltd.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; I-MAB Biopharma Co., Ltd.; ImmunoGen, Inc.; Incyte; InxMed; Karyopharm Therapeutics; Merck & Co., Inc.; Novocure GmbH; NRG Oncology; Onconova Therapeutics; Seagen Inc.; Sutro Biopharma, Inc.; Takeda Pharmaceutical Company Limited; Tesaro, Inc./GlaxoSmithKline; Toray Group; VBL Therapeutics; and Xencor.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, the Foundation for Women's Cancer, and the National Ovarian Cancer Coalition. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent educational grants from AstraZeneca, Eisai Inc., ImmunoGen, Inc., Karyopharm Therapeutics, and Merck & Co., Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit^TM into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.25 contact hour(s) and 1.25 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.25 AAPA Category 1 CME credits. Approval is valid until 4/17/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credits for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 12, 2025; credit is no longer available.

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
• Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
• Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
• Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 12, 2025; credit is no longer available.

A Joint Effort for Equitable Hemophilia A Care: Collaborative Solutions for Enhancing Outcomes in Diverse and Challenging Patient Populations

Media: Enduring Material
Activity Release Date: March 13, 2024
Activity Expiration Date: March 12, 2025
Time to Complete Activity: 60 minutes

Activity Description

While significant progress has been made in the management of severe hemophilia A (HA), the needs of those with mild and moderate HA, including females, have long been sidelined. Until now. Join two experts as they explore the latest evidence with available pharmacologic treatment options, including FVIII mimetics, that are paving the way for equitable HA care. Through interactive case discussions, the experts will provide collaborative solutions for overcoming challenges related to identifying, engaging, and managing individuals with severe and non-severe HA to ensure no one is left behind in the pursuit of equitable care.

Target Audience

This activity has been designed to meet the educational needs of hematologists, hematologist-oncologists, advanced practice clinicians, fellows, residents, and other healthcare professionals involved in the care of patients with hemophilia A.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Recognize unmet needs and barriers to equitable HA care, including among severe, nonsevere, and female HA populations
• Summarize the evidence supporting established treatment options, including FVIII mimetic agents, with applications in diverse HA settings, including severe, nonsevere, and female HA populations
• Develop individualized HA treatment plans with established therapeutics based on disease severity, inhibitor status, gender, and age, among other considerations
• Employ principles of equitable, team-based, and participatory care when managing persons with HA, to ensure appropriate patient education, adherence counseling, and prompt management of disease- or treatment-related events

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Amy Shapiro, MD
Medical Director and CEO
Indiana Hemophilia and Thrombosis Center (IHTC)
Indianapolis, Indiana

Amy Shapiro, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Be Biopharma; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; HEMA Biologics, LLC; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; and Sanofi-Genzyme.
Grant/Research Support from Agios Pharmaceuticals, Inc.; BioMarin; Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; Novo Nordisk Inc.; Pfizer; Regeneron Pharmaceuticals Inc.; Sanofi-Genzyme; Pharmacosmos A/S; and Takeda Pharmaceutical Company Limited.
Speakers Bureau participant with Genentech, Inc./F. Hoffmann-La Roche Ltd; Kedrion Biopharma Inc.; and Sanofi-Genzyme.
Other Financial or Material Support in the form as a board member of the Novo Nordisk Haemophilia Foundation. She is the Medical Director of the National Hemophilia Program and Coordinating Center of the American Thrombosis Hemostatis Network.

Faculty/Planner
Maissaa Janbain, MD, MSCR
Associate Professor of Clinical Medicine
Director
Tulane University
Deming Department of Medicine
Section of Hematology & Medical Oncology - Louisiana Center for Bleeding & Clotting Disorders
New Orleans, Louisiana

Maissaa Janbain, MD, MSCR, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Clovis Oncology, Inc.; Genentech, Inc.; GlaxoSmithKline; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi Genzyme; and Seagen Inc.
Grant/Research Support from AstraZeneca; Pfizer; and Seagen Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by educational grants from Genentech, a member of the Roche Group, and Novo Nordisk Inc.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/12/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 7, 2025; credit is no longer available.

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
• Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
• Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 7, 2025; credit is no longer available.

Exploring New Routes in Immuno-Oncology: Understanding the Role of Subcutaneous Immune Checkpoint Inhibitors & Preparing for Innovative Delivery Approaches in the Clinic

Media: Enduring Material

Activity Release Date: March 8, 2024

Activity Expiration Date: March 7, 2025

Time to Complete Activity: 30 minutes

Activity Description

In this video-based activity, an oncology expert discusses the role of subcutaneous (SC) immune checkpoint inhibitors in addressing unmet needs for the management of various solid tumors. Learn about evidence supporting SC administration of immune-oncology agents in different disease and treatment settings, and prepare to bring innovative formulations to the clinic.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, urologists, surgical oncologists, thoracic surgeons, NPs, PAs, nurses, pharmacists, and other healthcare professionals involved in the care of patients with cancer.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Explain the potential of subcutaneous routes of administration of immune checkpoint inhibitors to address unmet needs in various cancer settings
• Cite current evidence on the utilization of innovative routes of administration of immuno-oncology regimens when managing patients with cancer across different tumor and treatment settings
• Apply team-based strategies to integrate innovative formulations of immune checkpoint inhibitors in real-world practice based on the latest clinical evidence, patient preferences, and other healthcare system factors

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Prof. Laurence Albiges, MD, PhD

Full Professor of Medical Oncology

Chair of Medical Oncology Department

Gustave Roussy Institute

Villejuif, France

Prof. Laurence Albiges, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Amgen Inc.; Astellas Pharma US, Inc.; Bristol Myers Squibb; Eisai Inc.; F. Hoffmann-La Roche Ltd; Ipsen Biopharmaceuticals, Inc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme; Novartis Pharmaceuticals Corporation; and Pfizer Inc.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported through an educational grant from Bristol Myers Squibb.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 0.5 contact hour(s) and 0.5 contact hour(s) in the area of pharmacology.

Pharmacists

PVI, PeerView Institute for Medical Education, designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008289-0000-24-038-H01-P

Type of Activity: Knowledge

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until 3/7/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

For pharmacists, upon receipt of the completed activity evaluation form, you will receive an email from email@email.peerviewpress.com within 2 weeks with a link and directions to submit your credit to the NABP CPE Monitor Service. PVI, PeerView Institute for Medical Education, will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, you can view your participation record at the NABP website: mycpemonitor.net.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/CPE/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on February 28, 2025; credit is no longer available.

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.

In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
• Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
• Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on February 28, 2025; credit is no longer available.

REVIVE Initiative: Reinforcing Evidence-Based Principles Against Cancer-Associated Venous Thromboembolism

Media: Enduring Material

Activity Release Date: March 1, 2024

Activity Expiration Date: February 28, 2025

Time to Complete Activity: 45 minutes

Activity Description

Venous thromboembolism (VTE), is a significant complication in cancer patients and a leading cause of mortality in this setting. Despite the availability of numerous guidelines and resources for cancer-associated VTE prevention and treatment, the uneven implementation of effective anticoagulation remains a barrier to highly effective management.

In this PeerView virtual activity, a leading expert on cancer-associated VTE will provide clinical insights and case-based guidance on current prevention and treatment strategies for cancer-associated VTE. Throughout, the faculty will address modern prophylactic and therapeutic anticoagulation options, underscore the importance of risk assessment and timely management, and offer insights into the selection of anticoagulants. Additionally, the expert will highlight the importance of an interprofessional team-based approach, aligned with shared decision-making, when caring for patients at risk of cancer-associated VTE.

Target Audience

This activity has been designed to meet the educational needs of oncologists, NPs, PAs, and other care team clinicians involved in the prevention and management of cancer-associated VTE.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Cite recognized thromboembolic risk factors, guideline recommendations for modern risk assessment, and current evidence supporting modern anticoagulation strategies for cancer-associated VTE
• Implement risk-adapted prophylaxis and treatment strategies for cancer-associated VTE while employing the principles of equitable, team-based, and participatory care
• Manage practical aspects of VTE management in the cancer setting, including safe dosing and delivery of therapy, and provision of patient counseling on elevated VTE risks, adherence to treatment plans, and the risks/benefits of anticoagulation

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Alok A. Khorana, MD, FACP, FASCO

Sondra and Stephen Hardis Endowed Chair in Oncology Research

Vice-Chair, Taussig Cancer Center

Director, GI Malignancies Program

Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University

Cleveland, Ohio

Alok A. Khorana, MD, FACP, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Anthos Therapeutics; Bayer Corporation; Bristol Myers Squibb; Pfizer; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from the Bristol Myers Squibb and Pfizer Alliance.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until 2/28/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 23, 2025; credit is no longer available.

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.

In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
• Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
• Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
• Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on March 23, 2025; credit is no longer available.

Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Accelerating the Transition of Emerging Strategies to the Clinic

Media: Enduring Material

Activity Release Date: February 24, 2024

Activity Expiration Date: March 23, 2025

Time to Complete Activity: 60 minutes

Activity Description

In recent years, there have been notable advances in the treatment of small-cell lung cancer (SCLC). Several new options have now become guideline-recommended standards of care. Despite these advancements, the prognosis for SCLC remains poor. This justifies efforts to optimize and expand the use of approved treatments and explore novel therapies with different mechanisms of action. Several potential therapeutic strategies are currently under examination in clinical trials that will hopefully lead to a further expansion of the SCLC treatment arsenal.

In this PeerView educational activity, based on a recent live symposium, experts discuss the latest evidence, ongoing trials, clinical cases, and challenging questions to take a deeper dive into the nuances of how to optimally integrate the latest therapeutic advances into clinical practice. The faculty panel provides evidence-based and practical guidance to help the lung cancer care team better understand the current and evolving treatment arsenal for SCLC and improve the care and outcomes of patients with SCLC.

Target Audience

This activity has been designed to meet the educational needs of medical oncologists, advanced practice clinicians, and other clinicians involved in the management of SCLC.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Analyze the role and use of current and emerging therapies for SCLC, and the evidence that supports their use
• Incorporate current standard-of-care therapies into individualized treatment plans for patients with SCLC based on the latest evidence, guideline recommendations, and patient needs and preferences
• Recommend enrollment in clinical trials to eligible patients who could benefit from the current and emerging therapies
• Implement multidisciplinary/interprofessional strategies and shared decision-making to ensure optimal care, including effective management of AEs, throughout the disease continuum for each patient with SCLC

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner

Taofeek K. Owonikoko, MD, PhD

Executive Director, Marlene and Stewart Greenebaum Comprehensive Cancer Center

Marlene and Stewart Greenebaum Professor in Oncology

Senior Associate Dean of Cancer Programs, University of Maryland School of Medicine

Associate Vice President for Cancer Programs, University of Maryland, Baltimore

Chief of Service, University of Maryland Medical Center

Baltimore, Maryland

Taofeek K. Owonikoko, MD, PhD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for Abbvie Inc.; Amgen Inc.; AstraZeneca; Bayer Corporation; BeiGene, Inc.; Betta Pharmaceuticals Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Coherus BioSciences; Daiichi Sankyo, Inc.; Eisai Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GenCART; Gilead Sciences, Inc.; GlaxoSmithKline; Heat Biologics Inc.; Janssen Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Meryx Inc.; Novartis Pharmaceuticals Corporation; Oncocyte Corporation; OncoHost; Puma Biotechnology, Inc.; Regeneron Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Grant/Research Support from Amgen Inc.; AstraZeneca; Bayer Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Myers Squibb; Cardiff Oncology, Inc.; Cyclacel Pharmaceuticals, Inc.; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; GlaxoSmithKline; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Oncorus, Inc.; Pfizer; Puma Biotechnology, Inc; Turning Point Therapeutics, Inc.; and Y-mAbs Therapeutics, Inc.

Faculty/Planner

Anne Chiang, MD, PhD, FASCO

Associate Professor of Medicine

Associate Yale Cancer Center Director, Clinical Initiatives

Yale University School of Medicine

New Haven, Connecticut

Anne Chiang, MD, PhD, FASCO, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; Genentech, Inc.; and Janssen Pharmaceuticals, Inc.

Grant/Research Support from AbbVie, Inc.; Amgen Inc.; AstraZeneca; Bristol Myers Squibb; Flatiron Health; and Genentech, Inc.

Faculty/Planner

Jared Weiss, MD

Professor of Medicine

Section Chief of Thoracic and Head/Neck Oncology

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina

Jared Weiss, MD, has a financial interest/relationship or affiliation in the form of:

Consultant and/or Advisor for AbbVie Inc.; Amgen Inc.; AstraZeneca; EMD Serono, Inc.; G1 Therapeutics, Inc.; Genentech, Inc.; Genmab A/S.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Lilly; Nanobiotix; PDS Biotechnology; Pfizer; and Sanofi.

Grant/Research Support from G1 Therapeutics, Inc.; Inspirna, Inc.; and Lilly.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by independent medical education grants from AstraZeneca and Jazz Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points and patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 3/23/2025. PAs should only claim credit commensurate with the extent of their participation.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/AAPA/IPCE Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on February 6, 2025; credit is no longer available.

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
• Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
• Select and monitor treatment for patients with BP according to updated guidelines
• Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView

This activity expired on February 6, 2025; credit is no longer available.

Addressing Unmet Patient Needs in Bullous Pemphigoid: Exploring Targeted Treatment for Safe and Effective Care

Media: Enduring Material
Activity Release Date: February 7, 2024
Activity Expiration Date: February 6, 2025
Time to Complete Activity: 60 minutes

Activity Description

Bullous pemphigoid (BP) is a rare autoimmune subepidermal blistering disease characterized by large, tense blisters in the skin preceded by urticarial plaques and pruritus. It occurs most frequently in elderly patients, with risk rising exponentially after the age of 80. Diagnosis is often missed or delayed, partly due to it being a rare disorder, and partly due to atypical presentations or similarities with other skin conditions.

Although management guidelines have been updated there is still a lack of consensus on optimal treatment regimens and duration. Systemic corticosteroids and other immunosuppressive agents carry risks of adverse events; thus, targeted agents that are already approved for other diseases are under study for their utility in BP.

In order to help dermatologists and other clinicians treating patients with BP remain updated on advances in treatment, PeerView has prepared this discussion between two expert dermatologists. Learners will hear about the impact of BP on patient quality of life and how to differentiate BP from other skin conditions, as well as how to treat patients using the latest guidelines and targeted therapy.

Target Audience

This activity has been designed to meet the educational needs of dermatologists, dermatology advanced practice providers, and other clinicians who care for patients with bullous pemphigoid.

Educational Objectives

Upon completion of this activity, participants should be better able to:

• Identify and differentiate bullous pemphigoid (BP) from other skin conditions that can present similarly, based on current guidelines and expert recommendations
• Discuss the impact of BP on elderly patients with regard to morbidity/mortality and quality of life, particularly for those with several comorbidities
• Select and monitor treatment for patients with BP according to updated guidelines
• Explain the rationale to improve outcomes for patients with BP through the use of targeted therapy

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to control the content of a CE activity, including faculty, planners and reviewers are required to disclose all financial relationships with ineligible companies (commercial interests) that as an entity produces, markets, re-sells or distributes healthcare goods or services consumed by or used on patients. All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Faculty/Planner Disclosures

Co-Chair/Planner
Erin X. Barrett (Wei), MD
Associate Professor of Dermatology
University of Nebraska Medical Center/Nebraska Medicine
Co-Director of the Bullous Disease Clinic
Director of Clinical Trials
Director of Inpatient Dermatology Services
Director of the Skin of Color/Ethnic Skin Dermatology Clinic
Omaha, Nebraska

Erin X. Barrett (Wei), MD, has no financial interests/relationships or affiliations in relation to this activity.

Co-Chair/Planner
David Rosmarin, MD
Chair, Kampen-Norins Scholar
Indiana University
Indianapolis, Indiana

David Rosmarin, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AbbVie Inc.; Abcuro, Inc; AltruBio, Inc.; Arena Pharmaceuticals, Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol Meyers Squibb; Celgene Corporation; Concert Pharmaceuticals, Inc.; CSL; Dermavant Sciences, Inc.; Dermira, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Kyowa Kirin Co., Ltd.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; Recludix; Revolo Biotherapeutics; sanofi-aventis U.S. LLC; Sun Pharmaceutical Industries, Ltd.; UCB; and Viela Bio, Inc.
Grant/Research Support from AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermira, Inc.; Galderma S.A. ; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; and Regeneron Pharmaceuticals Inc.
Speaker for AbbVie Inc.; Amgen Inc.; Bristol Meyers Squibb; Celgene Corporation; Dermavant Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Lilly; Novartis Pharmecuticals Corporation; Pfizer; Regeneron Pharmaceuticals Inc.; and Sanofi.

Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Accreditation, Support, and Credit

In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Support

This activity is supported by an educational grant from Sanofi and Regeneron Pharmaceuticals.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points  in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity will be awarded 1.0 contact hour(s) and 1.0 contact hour(s) in the area of pharmacology.

Physician Assistants

PVI, PeerView Institute for Medical Education, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 2/6/2025. PAs should only claim credit commensurate with the extent of their participation.

Method of Participation

There are no fees for participating in or receiving credit for this CE activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

If requesting MOC/CC credit, the post-test and evaluation are required in their entirety as well as your Board Unique ID number, DOB (MM/DD), and a score of 75% or higher is needed to obtain MOC/CC credit.

For nurses, the post-test and evaluation form are required in their entirety and a score of 75% or higher is needed to obtain Nursing Continuing Professional Development (NCPD) credit. There are no prerequisites and there is no fee to participate in this activity or to receive NCPD credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

About This CME/MOC/NCPD/AAPA Activity

PVI, PeerView Institute for Medical Education, is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PVI, PeerView Institute for Medical Education, or any of its partners, providers, and/or supporters.

Copyright © 2000-2024, PeerView